Overview of Dr. Akce
Dr. Mehmet Akce is an oncologist in Birmingham, AL and is affiliated with The University of Alabama at Birmingham. He received his medical degree from Marmara University Faculty of Medicine and has been in practice 8 years. He specializes in gastrointestinal cancer and hematologic oncology and is experienced in gallbladder cancer, gastric cancer, pancreatic cancer, chemotherapy, and hepatobiliary cancer.
Office
619 19th St S
Birmingham, AL 35233
Education & Training
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2014 - 2017
Trinity Health Ann Arbor HospitalChief Residency, Internal Medicine, 2013 - 2014- Trinity Health Ann Arbor HospitalResidency, Internal Medicine, 2010 - 2013
Marmara Univ- Fac MedClass of 2009
Certifications & Licensure
GA State Medical License 2017 - 2026
AL State Medical License 2022 - 2025
MI State Medical License 2010 - 2014- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer Start of enrollment: 2019 Jan 15
- A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab Start of enrollment: 2023 Jan 19
Roles: Contact, Principal Investigator
- Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer Start of enrollment: 2023 Jul 01
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Triplet regimen with camrelizumab plus apatinib in combination with hepatic artery infusion chemotherapy (HAIC): a new treatment paradigm for select patients with Barc...Garima Gupta, Reema Patel, Mehmet Akce, Aman Chauhan
Chinese Clinical Oncology. 2024-10-01 - Association between frailty and overall survival among older adults with hepatocellular carcinoma.Ahmet Anil Ozluk, Grant Richard Williams, Chen Dai, Jonathan Goldberg, Midhun Malla
Journal of Geriatric Oncology. 2024-09-01 - 6 citationsImpact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis.Mohammad Saeid Rezaee-Zavareh, Yee Hui Yeo, Tielong Wang, Zhiyong Guo, Parissa Tabrizian
Journal of Hepatology. 2024-07-10
Journal Articles
- The Potential of CAR T Cell Therapy in Pancreatic CancerMehmet Akce, Mohammad Y Zaidi, Edmund K Waller, Frontiers in Neurology
Lectures
- The impact of inflammatory biomarkers, BMI, and sarcopenia on survival in advanced hepatocellular carcinoma treated with immunotherapy.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Impact of high-risk features for stage II adenocarcinoma of the appendix.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies: Results of the dose-escalation phase.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
Press Mentions
Hepatocellular Carcinoma, Novel Therapies on the HorizonJuly 22nd, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
